
FDA Approves First Standalone Robotic Blood-Drawing Device
The story in brief
The FDA authorized the Aletta, a standalone robotic blood-drawing device, through its De Novo pathway, making it the first of its kind to receive such approval. Already in use in Europe as part of a clinical trial, the Aletta uses near-infrared light and real-time ultrasound to locate veins. A phlebotomist can oversee up to three devices at once, addressing staffing shortages in U.S. labs, which reported a 9.4% vacancy rate in phlebotomy positions.